Retrospective analysis of predictive factors for pathological complete response after neoadjuvant chemotherapy in gastric cancer

Table 3 Influence of chemotherapy regimens and cycles on pathological complete response rates

Factor	Category	pCR rate (%)	P value
Chemotherapy regimen	Platinum compound type
	Oxaliplatin-containing (FLOT, SOX, XELOX)	22.3%	0.034
	Cisplatin-containing (DCF)	12.7%	-
	Specific regimen		0.023
	FLOT	27.5%
	SOX	18.2%
	XELOX	15.4%
	DCF	11.8%
Chemotherapy cycles	General comparison
	≥ 4 cycles	24.8%	0.006
	< 4 cycles	11.2%	-
	Detailed cycle ranges	-	N/A
	2-3 cycles	11.2%
	4-5 cycles	21.6%
	6 cycles	28.3%
	> 6 cycles	27.9%

FLOT: Fluorouracil, leucovorin, oxaliplatin, docetaxel; SOX: S-1, oxaliplatin; XELOX: Capecitabine, oxaliplatin; DCF: Docetaxel, cisplatin, fluorouracil; pCR: Pathological complete response; N/A: Not applicable.